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Abstract
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are the leading
cause of all nosocomial, or healthcare-associated (HAI), infections (Navidinia, 2016). The
purpose of this research study is to determine the burden of ESKAPE infections on healthcare
and study the antibiotic resistance in these high-risk pathogens to provide direction for
researchers to develop new antimicrobial innovations to reduce ESKAPE infectivity and improve
patient outcomes. To study the burden of ESKAPE infections, this review analyzes the current
statistics explaining the clinical prevalence of each pathogen in causing HAIs. Additionally, each
pathogen is investigated to determine the health risks and factors that make certain communities
more susceptible to infection. To study the mechanisms of resistance, numerous studies across
molecular biology are utilized to provide a comprehensive report of existing and emerging
resistance patterns.
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Introduction
Antimicrobial resistance (AMR) has been declared “one of the top 10 global health
threats facing humanity” by the World Health Organization (WHO) (Ghosh, 2021). AMR occurs
due to adaptations in the bacteria, viruses, fungi, and parasites that cause illnesses. These
adaptations cause the treatments currently available to be less effective or not effective at all to
stop an infection (World Health Organization, 2021). Pathogens with antimicrobial resistance are
emerging rapidly in clinical settings. The ESKAPE pathogens (Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas
aeruginosa, and Enterobacter species) are the leading cause of all nosocomial, or healthcareassociated (HAI), infections (Navidinia, 2016). The Centers for Disease Control and Prevention
estimates that in the United States alone, more than 2.8 million antibiotic-resistant infections
occur yearly. The annual cost to treat these infections is over $4.6 billion in America (Nelson et
al., 2021). From a global public health perspective, the growing prevalence of infectious diseases
is overwhelming the healthcare industry and increasing the risk of severe or deadly infections in
human patients. Prolonged infections lead to longer inpatient admissions and extensive
medication regimens which are long-term burdens for patients.
The purpose of this research study is to determine the burden of ESKAPE infections on
healthcare. Additionally, studying the molecular mechanisms of antibiotic resistance in these
high-risk pathogens will provide direction for pharmaceutical researchers to develop new
antimicrobial innovations to reduce ESKAPE infectivity and improve patient outcomes. For this
literature review, an interdisciplinary analysis utilizing public health, medical, biological, and
statistical concepts is required.
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Clinical Prevalence
ESKAPE pathogens are uniquely characterized by the pathogenic nature of the bacteria
and characteristics of antimicrobial resistance. In the Arbune 2021 retrospective study of
ESKAPE prevalence in a Romanian hospital from 2015-2020, researchers collected 4293 isolates
from patients with nosocomial bacterial infections. S. aureus was the ESKAPE pathogen with
the highest prevalence with 26% of the samples testing positive. In decreasing order of
prevalence, K. pneumoniae (9.55%), P. aeruginosa (8.78%), and Enterococcus species (3.55%)
were found. Enterobacter and Acinetobacter species were not found in significant quantities
(Arbune et al., 2021).

Enterococcus Species
E. faecium and Enterococcus faecalis are Gram-positive opportunistic pathogens which
can cause HAIs. E. faecium and E. faecalis typically inhabit the gastrointestinal tract in humans
and under normal conditions are nonpathogenic. Sequencing data has classified the E. faecium
population into two clades, clade A and clade B, where HAIs are associated with clade A (Zhou
et al., 2020).
Of the 148 strains of Enterococcus in the Arbune 2021 study, only samples collected
from 2019 were identified at the species level. In the 26 specific cases that were identified, two
were E. faecium and 24 were E. faecalis. Ciprofloxacin (CIP) sensitivity was low in all samples.
Of the E. faecium samples, linezolid and vancomycin were effective (Arbune et al., 2021).
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Staphylococcus aureus
S. aureus is commonly part of the skin microbiota and can be well isolated from the
nostrils and other moist environments. S. aureus takes advantage of wounds and lesions to cause
infections. S. aureus can present as an acute or chronic infection. Chronic infections are
exacerbated by the ability of the pathogen to create biofilms in post-operative recovery
(Pendleton et al., 2014). Biofilm-associated infections are generally not susceptible to
antimicrobial treatments because of the protective exocellular matrix and subpopulations of
dormant persistent cultures of cells leading to chronic infections. A large majority of S. aureus
infections are additionally intensified by the pathogen’s ability to secrete hyaluronidase and
collagenase, which are two enzymes that cause tissue deterioration in the epidermis and dermis
of infected patients (Pendleton et al., 2014). Many different types of collagenase exist and are
considered a virulence factor as they aid in the breakdown of peptide bonds in collagen in
connective tissues. This increases the penetration of pathogens and subsequent movement to
establish infection within the tissue, and provides nutrients and host factors for sustained
pathogenic presence. In roughly 25% of isolates, S. aureus utilizes exotoxin TSST-1, which
causes gastroenteritis (Pendleton et al., 2014).
In the Arbune study, S. aureus was identified as 89% of all Staphylococcal isolates.
While the S. aureus isolates had several effective antibiotics against them, the Methicillinresistant Staphylococcus aureus (MRSA) isolates were not as susceptible as the non Methicillinresistant S. aureus strains.
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Klebsiella pneumoniae
K. pneumoniae is a Gram-negative Enterobacteriaceae that can be found in the flora of
the mouth, skin, and intestines in humans. It is non-motile, encapsulated, and a facultative
anaerobe. Klebsiella species were identified in roughly 5% of bacteremia diagnosis from a study
in the UK (Pendleton et al., 2014). Fimbrial adhesins and a thick capsule physically prevent the
immune cells of the host from phagocytosing the pathogen, known as antiphagocytic protection.
When pathogens can evade the natural defense of the host’s immune system, the typical limits
for pathogen growth and spread are not capable of slowing or stopping infection, which leads to
more aggressive infectivity.
In the 2021 Arbune study, K. pneumoniae susceptibility was decreased against
sulfamethoxazole-trimethoprim, ciprofloxacin, gentamicin, meropenem, and beta-lactamines.

Acinetobacter baumannii
A. baumannii is a Gram-negative, rod-shaped opportunistic pathogen commonly seen in clinical
settings including intensive care units and surgical wards (Pendleton et al., 2014).
Interestingly, during the Iraq War, "Iraqibacter" or A. baumannii became a nosocomial infection
in US military healthcare treatment facilities. It continued to be a source of infections for those
who served in the Afghanistan War as well. The A. baumannii drug resistance strains have
moved to civilian clinical spaces as infected military personnel were moved to these different
healthcare institutions for their care. Other Acinetobacter species are typically isolated from soil
samples, but A. baumannii is primarily isolated from clinical settings (Antunes et al., 2014).
These particular clinical settings overuse antibiotics to permit resistance to be generated. A.
baumannii is highly adapted to thrive in clinical environments by transfer of resistance genes.
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In the Arbune study, A. baumannii was identified in 19 samples collected from skin
infections, urine and blood cultures, airway secretions, and catheter sites. Resistance against
cephalosporins, quinolones, and aminoglycosides was noted.

Pseudomonas aeruginosa
P. aeruginosa, a Gram-negative facultative anaerobe, can thrive in mucosa. The
opportunistic pathogen is most commonly identified in patients diagnosed with cystic fibrosis,
cancers, or burn victims (Pendleton et al., 2014). P. aeruginosa produces multiple secondary
metabolites, polymers, and can use various carbon sources and electron acceptors for energy
leading to widespread presence in clinical settings and resistance to antibiotics. As it can survive
on abiotic and biotic surfaces in biofilms, P. aeruginosa is common as a HAI including
ventilator-associated pneumonia, central line-associated bloodstream infection, urinary catheterrelated infection, and surgical/transplantation infections. Biofilms that form within the
respiratory tract of cystic fibrosis patients are harder to treat due to the more embedded nature of
the biofilms in the excess mucus and cilia of the lungs. The antibiotic concentration to kill the
bacteria within these biofilms is 1,000 times the strength of the minimum inhibitory
concentration (Gnanadhas et al., 2015).
In the Arbune study, 204 strains of P. aeruginosa were found from primarily skin
infections. The Multidrug resistant (MDR) rate was 29.1%. The collected strains lacked
complete susceptibility to all of the tested antibiotics (amoxicillin clavulanate, cefuroxime,
cefotaxime, ceftazidime, cefepime, piperacillin- tazobactam, ertapenem, meropenem,
ciprofloxacin, gentamicin, and sulfamethoxazole-trimethoprim).
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Enterobacter species
The Enterobacter genus consists of 22 species of opportunistic pathogens, all of which
are facultative anaerobes. Enterobacter species are also found as commensal bacteria in the gut
microbiota. The most common causes of nosocomial infections are Enterobacter aerogenes, E.
cloacae, and E. hormaechei. These pathogens commonly infect patients in intensive care units
because these immunocompromised patients are at higher risk due to prolonged recent use of
antimicrobial treatment and use of invasive procedures with medical devices. Biofilms can also
survive on these medical devices and within the patient, making these bacteria excellent
colonizers (Davin-Regli, et al., 2019).

Health Risks and Factors
Each pathogen species has unique risk factors and impacts populations differently. HAIs
primarily fall into the following categories: central line-associated bloodstream infections,
catheter-associated urinary tract infections, surgical site infections, and ventilator-associated
pneumonia (Centers for Disease Control and Prevention, 2014).
Enterococcus species cause life-threatening infections in various sites, including the
bloodstream, surgical sites, and urinary tract infections. In 2017, there were 54,500 cases in
clinical settings and 5,400 deaths in the United States (Arroyo Pulgar, 2019).
Immunocompromised patients face heightened likelihood of an adverse infection because their
immune systems are weakened and unable to fend off aggressive infections that require immune
intervention (Pendleton et al., 2014).
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S. aureus is typically found in the normal skin microbiota of humans. Most S. aureus
infections are found in superficial locations, including skin lesions and wounds (Arroyo Pulgar,
2019). Specifically, communities of patients with postoperative lesions and wounds are at a
higher risk to develop a serious S. aureus infection. Typically, the mucus membranes and skin
form physical barriers to prevent infection. However, if lesions or wounds exist, pathogens can
access the deeper tissues and thrive from the abundant nutrients available in the new
environment to form infections. Surgical site infections are common causes of further
complications, and readmission to the hospitals with increased morbidity and mortality.
Therefore, patients with postoperative lesions at highest risk for developing nosocomial S.
aureus infections.
K. pneumoniae impacts the young, the old, and immunocompromised individuals most
commonly (Pendleton et al., 2014). K. pneumoniae is naturally found in the human
gastrointestinal system. Patients receiving care in clinical settings, especially individuals who
require medical devices as interventions, face an increased risk of developing an infection. This
is because the medical devices act as mediums to allow the pathogen to access more susceptible
locations of the body that lack protective epithelial tissue (Centers for Disease Control and
Prevention, 2010).
A. baumannii impacts patients who use antibiotics prior to infection. Typically, the
pathogen exhibits more resistance in respiratory infections in comparison to the infections found
in the bloodstream, urinary tracts, or skin lesions (Ellis et al., 2015).
P. aeruginosa impacts immunocompromised individuals most severely. Individuals with
chronic lung diseases including asthma, cystic fibrosis, and chronic obstructive pulmonary
disease are at the highest risk of severe infection (Arroyo Pulgar, 2019).
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Enterobacter species can infect the circulatory, respiratory, and urinary systems, making
those with relevant preexisting conditions such as diabetes, cancer malignancy, and lupus more
susceptible (Arroyo Pulgar, 2019) (Pendleton et al., 2014). Immunocompromised patients are
most at risk for chronic Enterobacter-caused infections.

Molecular Mechanisms of Resistance
AMR naturally occurs as bacteria evolve. Resistance first arose with antibiotics
intrinsically, without the requirement of direct antibiotic treatment. These mutations against
antimicrobial susceptibility are encouraged when antibiotics are applied, and the only remaining
bacteria are those with the resistance traits. Misuse of antibiotics in modern times occurs both in
clinical and non-clinical settings. Incorrect prescribing (dosing and duration-decision making) is
a large issue in clinical settings (Homes et al., 2015; Ayobami et al., 2022). Overprescribing of
antibiotics increases the risk of adverse effects and more frequent reinfections due to a decrease
of the natural flora in the body. People also often do not complete their antibiotic course of
medicine once they are feeling better which can lead to development of antibiotic resistance. In
addition, antibiotics are sometimes prescribed when infections are viral, which is an ineffective
course of treatment for any infection that is not bacterial.
Other larger-scale antibiotic misuse occurs in the agricultural sector, where antibiotics
cause increased growth promotion for better yields. Economically, utilizing antibiotics in
agriculture allows farmers to make larger profits in less time as they do not need to wait for
livestock to mature as long. Excess antibiotic use can collect within the farming system in soil,
run-off, and sewage, which contains naturally-occurring microorganisms. Once these
microorganisms develop resistance against the antibiotics contaminating the environment, the
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microorganisms and residual antibiotics are able to spread outside of the confined agricultural
setting.
The WHO collaborative project, One Health, provides an explanation about the
relationship between human health and our physical environment. The One Health initiative
explains that the overuse and abuse of antibiotics in human medicine, agriculture, and our
environment have all contributed to the AMR public health crisis (McEwen and Collignon,
2018). One Health focuses on the impact of humans, animals, plants, wildlife, and the
environment on antimicrobial overuse and antimicrobial resistance. Some examples include
studies on large-scale, low-dose antibiotic feeding of animals with common antimicrobials in
commercialized agriculture where the target consumers are humans. Additional studies within
the initiative focus on the importance of how good hygiene, infection control, drinking water,
sanitation, and the prevention of pollution from industrial, residential, and farm waste can help
control antimicrobial resistance.
Broadly, antibiotic resistance can occur by mutation or horizontal gene-transfer (HGT).
Mutations leading to AMR typically occur in three classes of genes: genes that encode the targets
of the antibiotic, genes that encode their transporters, and genes that encode the regulators that
repress the expression of transporters. The genetic resistome includes the mobile genetic
elements and other relevant antibiotic resistance genes in pathogens which pathogenic bacteria
can acquire via horizontal gene transfer (HGT) (Wright, 2007). The HGT mechanisms of
conjugation, transformation, and transduction lead to spread of antibiotic resistance
nonspecifically between non-pathogenic species to pathogenic species. This allows bacteria to
develop resistance traits without needing to be exposed directly to the antimicrobial treatment
itself. Conjugation is the transfer of DNA through a multi-step process requiring cell to cell
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contact via cell surface pili or adhesins. In the transformation process, bacteria can uptake and
express extracellular DNA fragments. In transduction, the bacteriophages can transfer genes to
bacterial pathogens. For horizontal gene transfer, the idea that the genes for antibiotic resistance
must come from the environmental microorganisms that produce antibiotics is shown to be false
with the examples of two known genetic resistances coming from Shewanella algae and
Kluyvera which are not antibiotic producers.
Resistance can be grouped functionally into mechanisms that modify the target of an
antibiotic or those that modify the concentration of the antibiotic. Antibiotic concentration can be
reduced by impeding entry of the antibiotic, extruding the antibiotic through efflux pumps, or
changing the structure of the antibiotic by antibiotic-inactivating enzymes or mutations in the
enzyme that activates a pre-antibiotic. (Martinez, 2014). Mechanisms of drug resistance fall into
several broad categories: drug inactivation and alteration, modification of drug binding sites,
changes in the permeability of the cell, and biofilm formation (Santajit and Nitaya, 2016).
With drug inactivation and alteration, bacteria can synthesize enzymes that inactivate
antibiotics by altering the structure of the drug. The most prevalent example is the production of
β-lactamases. These enzymes hydrolyze the β-lactam rings within the structure of the β-lactam
antibiotic class. The most common classification system for β-lactamases is the Ambler system,
which groups β-lactamases by amino acid sequence (Hall and Barlow, 2005). β-lactams include
penicillins, cephalosporins, monobactams, and carbapenems. Extended spectrum β-lactamases
(ESBLs) are a significant type of β-lactamase that falls in the molecular classification of Ambler
class A enzymes, with serine active-sites. ESBLs include CTX-M β-lactamases, which have been
identified in ESKAPE pathogens. The enzyme responsible for this particular ESBL phenotype
not affecting ceftazidime was named as CTX-M-1 in reference to its preferential hydrolytic
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activity against cefotaxime. Imipenemase (IMP) metallo-β-lactamases (MBLs) were found in P.
aeruginosa, K. pneumoniae, A. baumannii, and Enterobacter cloacae, whereas Verona integron
encoded metallo-β-lactamases (VIM-type) enzymes were in P. aeruginosa and A. baumannii.
MBLs are characterized by the necessity of zinc as a cofactor (Canton et al., 2012).
Carbapenemases such as KPC-1 (found in K. pneumoniae) causes resistance to imipenem,
meropenem, amoxicillin/clavulanate, piperacillin/tazobactam, ceftazidime, aztreonam, and
ceftriaxone (Santajit and Nitaya, 2016).
The modification of drug binding sites is another key mechanism of resistance exhibited
by the ESKAPEs. Penicillin-binding proteins (PBPs) are proteins used in the synthesis of the
peptidoglycan component of bacterial cell walls. Mutations in PBP structure prevent effective
binding of penicillin to the bacterial cell wall with mutated PBP, so penicillins are not effective
as an antimicrobial agent in PBP-mutated bacteria. Mutations cause a lower affinity for βlactams including methicillin that prevents antimicrobial activity on the bacteria. Some
pathogens are able to alter the peptidoglycan cross-link target so that D-Ala-D-Ala can alter to
D-Ala-D-Lac or D-Ala-D-Ser. This increases resistance to glycopeptides such as vancomycin
and teicoplanin, and this alteration is completed when the gene cluster Van-A through Van-G is
impacted (Santajit and Nitaya, 2016). Like β-lactams, glycopeptides also kill bacteria by
inhibiting cell wall synthesis. However, unlike β-lactams, vancomycin and teicoplanin do not
directly interact with PBPs. Instead, glycopeptides bind to the terminal D-alanine-D-alanine (DAla-D-Ala) of peptidoglycan, to prevent PBP-mediated cross-linking, to stop cell wall synthesis
and lead to bacterial death. However, when pathogens are able to alter their peptidoglycan crosslink target so that D-Ala-D-Ala becomes D-Ala-D-Lac or D-Ala-D-Ser, there is increased

Attre 16

resistance to glycopeptides such as vancomycin and teicoplanin and survival of bacteria in the
presence of these antibiotics.
Increasingly, researchers are focusing on the ability of bacteria to reduce the relative
intracellular drug accumulation. Efflux pumps are of interest in bacteria as the transmembrane
pump is able to decrease the concentration of an antibiotic within the cell of a pathogen, reducing
the susceptibility of the bacteria. Efflux pumps are used to pump toxins, heavy metals, and
metabolites out of the cell. Evolutions have allowed efflux pumps to also pump antibiotics out of
the cell either specifically by electrostatic interactions or generically using size cutoff. Many
efflux pumps that use ATP or a chemical gradient as an energy source to transport the antibiotics
out of the cell against the concentration gradient. The five super families of efflux pumps are the
ATP-binding cassette (ABC) family, the small multidrug resistance family, the major facilitator
superfamily, the resistance-nodulation-division (RND) family, and the multidrug and toxic
compound extrusion family (Santajit and Nitaya, 2016). Virtually all microorganisms have
conserved genetic sequences that encode efflux pumps. In Gram-negative bacteria, complex
multi-layered RND family pumps are used. Efflux pumps remove a broad spectrum of antibiotics
including fluoroquinolones, β-lactams, tetracycline and linezolid.
Porins are proteins that span across the outer membranes of Gram-negative bacteria that
create channels through which antibiotics can enter or exit the cell. Porins are large enough in
size to act as a channel to allow for passive diffusion of specific molecules. The molecule of
focus for each porin is typically specified by the size of the porin. Some, extremely selective
porins, are smaller than typical porins and can favor anions or cations for diffusion based on the
amino acids lining the channel (Choi and Lee, 2019). Reduction in the number of porins
decreases the influx of antimicrobial agents into bacteria allowing them to develop resistance
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against different antimicrobials. In many of the ESKAPEs, the reduction in the number of porins
and mutations that impact the porin size create a resistance against a variety of antibiotics. MDR
K. pneumoniae also utilizes porin reduction to prevent susceptibility to β-lactams (Santajit and
Nitaya, 2016).
Biofilm formation can occur on biotic or abiotic surfaces. These microbial communities
allow microorganisms to interact with the environment and can extend the longevity of bacterial
risk. Biofilms thrive through the process of adhesion, growth and maturation, and detachment.
This process protects pathogens from harmful conditions. When biofilms form, the
microorganisms can withstand the typically lethal fluctuations of pH, oxygen availability, and
temperature (Santajit and Nitaya, 2016). The physical protection provided to the pathogens by
biofilms coupled with uptake of resistance genes by HGT within the biofilm causes failure of
antibiotic treatments. The only way to remove pathogenic biofilms often includes removal of
implants and prosthetic biomaterials from the patients.

Enterococcus Species
Enterococcus species exhibit ampicillin and vancomycin resistance. Nearly all E. faecium
nosocomial infections exhibit β-lactam antibiotic resistance (Pendleton et al., 2014). There are
six types of vancomycin resistant Enterococcus (VRE), Van-A, Van-B, Van-C, Van-D, Van-E,
and Van-G. Van-A is most common and shows highest levels of resistance against glycopeptide
antibiotics due to the altering of the terminal sequence of cell wall precursors to decrease the
binding affinity of the glycopeptide to the cell wall (Pendleton et al., 2014). Enterococcal surface
protein (ESP) positive strains create thicker abiotic and biotic biofilms which restricts the
effectiveness of antimicrobial agents on the pathogen (Pendleton et al., 2014). E. faecium and E.
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faecalis, are able to alter the peptidoglycan cross-link target so that glycopeptide antibiotics are
ineffective against the pathogens (Santajit and Nitaya, 2016).

Staphylococcus aureus
Excessive use of penicillin for traditional infections created a positive pressure to
maintain and enhance resistance against β-lactams in Staphylococcus isolates. MRSA currently
accounts for 25% of S. aureus collections. Typically, glycopeptide antibiotics including
vancomycin and teicoplanin are first prescribed, but now there is developing vancomycinintermediate and vancomycin-resistant S. aureus, known as VISA and VRSA respectively. VISA
is characterized by the increased cell wall thickness due to upregulation of related genes (glmS,
vraR/S, sgtB, murZ, and PBP4), which reduces or prevents vancomycin functionality (Cui et al.,
2021). VISA is therefore difficult to treat and requires novel or uncommon antimicrobial
therapies to treat (Pendleton et al., 2014). VRSA has a unique set of resistance genes making it
difficult to treat: this pathogen has mec-A, a gene which encodes an alternative PBP, and van-A
resistances (Wielders et al., 2002). In S. aureus, the penicillin binding protein, PBP2a, prevents
antimicrobial activity on the bacteria. S. aureus is also capable of forming biofilms (Santajit and
Nitaya, 2016).

Klebsiella pneumoniae
More β-lactamases have been found in K. pneumoniae recently, which are enzymes that
alter the structure of β-lactam antibiotics. Carbapenem-resistant K. pneumoniae (CRKP), with
resistance encoded by blaKPC, is clinically prevalent as carbapenems are typically used to treat
chronic infections. The proportion of CRKP infections in clinical settings is directly correlated to
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the rise of the prevalence of the enzyme, New Delhi metallo-β-lactamase-1 (NDM-1) which has
carbapenem neutralizing activity (Pendleton et al., 2014; Moellering, 2010). CTX-M βlactamases have been identified in K. pneumoniae. Efflux pumps have been found in K.
pneumoniae isolates related to HAIs. Additionally, K. pneumoniae can form biofilms (Santajit
and Nitaya, 2016).

Acinetobacter baumannii
This pathogen can be highly infectious and cause increased rates of illness due to
effortless cross contamination as A. baumannii has a long survival time on hands and high-touch
surfaces in clinical settings, and can form biofilms. Carbapenemase-producing A. baumannii
strains carry IMP metallo-β-lactamases and oxacillinase serine β-lactamases. The AMR against
colistin and imipenem makes the typical antibiotic treatments ineffective (Pendleton et al., 2014).
CTX-M β-lactamases have been identified in A. baumannii. An MDR phenotype occurs when
there is an overexpression of RND-type efflux pumps. The susceptibility to fluoroquinolones, βlactams, tetracyclines, and aminoglycosides is lost (Santajit and Nitaya, 2016).

Pseudomonas aeruginosa
P. aeruginosa commonly is resistant to imipenem due to a combination of chromosomal
AmpC production and porin change (Pendleton et al., 2014). AmpC enzymes are encoded within
the chromosomal data within P. aeruginosa and act as β-lactamases (Jacoby et al., 2009). This
pathogen also produces extended spectrum β-lactamases (ESBL) (Chouchani et al., 2011). CTXM β-lactamases have been identified in P. aeruginosa. The bacteria also exhibits multiple efflux
pumps, including four RND-type MDR pumps which causes resistance against carbapenems,
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fluoroquinolones, and aminoglycosides. Additionally, the species is capable of forming biofilms
(Santajit and Nitaya, 2016).
Enterobacter species
Many Enterobacter variants utilize ESBLs and carbapenemases, including Verona
integron-borne metallo- β-lactamase (VIM), oxacillin hydrolyzing enzymes (OXA), metallo-βlactamase-1, and K. pneumoniae carbapenemase (KPC) (Arnold et al., 2011, Evans and Amyes,
2014). Only tigecycline and colistin are effective against highly resistant Enterobacter species
(cloverbio_webadmin, 2022). CTX-M β-lactamases have been identified in Enterobacter
species. Additionally, efflux pumps are present in HAI-causing Enterobacter aerogenes along
with porin reduction (Santajit and Nitaya, 2016).

Conclusion
With both an economic burden and a negative impact on global public health, combatting
the ESKAPEs requires continuous interdisciplinary studies. While this review utilizes research
across the fields of public health, medicine, molecular biology, and statistics, limitations of the
current research naturally exist. The ESKAPEs are constantly evolving and mutating to adapt to
their environment and overcome the pressures of the antimicrobial therapeutic agents. As new
therapeutic agents have to be discovered and strategic approaches must be applied, the data from
the current research will soon be outdated. As it is not possible to compare all emerging
therapies, combination therapies, and alternative therapeutic approaches, this analysis is not fully
comprehensive in nature.

Attre 21

The few remaining antibiotics that have not been overused need to be kept to minimal use
and rationed carefully. Across the healthcare system internationally, medical providers must be
more cautious when prescribing these medications. Additionally, patients are sometimes noncompliant and do not complete their full antibiotic therapy if they feel better, which allows
antibiotic resistance to develop due to low antimicrobial pressure on the microorganisms.
Healthcare providers must ensure the patient is adequately educated on medication management
and the necessity of completing a treatment course. However, non-compliance is not always due
to an educational issue; instead it can be due to patients experiencing side effects that can lead to
non-compliance. There are systemic barriers that limit ideal patient care: limited
transportation/excessive traveling to different areas, complex medication management between
acute and chronic conditions, and underlying comorbidities that may interfere with treatment
options. Additionally, knowledge of endemic susceptibility patterns and surveillance are relevant
to ensure antimicrobial stewardship. It is important for a medical provider to utilize an optimal
holistic approach and understand their patients unique circumstances while prescribing antibiotic
therapy for their specific infection.
As Levy and Marshall stated in the 2004 article, “Antibacterial resistance worldwide:
causes, challenges and responses” antibiotic resistance has been exacerbated due to “--the legacy
of past decades of antimicrobial use and misuse.” The article, ahead of its time, appropriately
declares this antimicrobial resistance as a global public health threat, where the entire population
is at risk due to an increasing presence of drug-resistant pathogens.
Ongoing research and pharmaceutical objectives must focus on creating new therapies to
combat the ever-evolving pathogens. This review thoroughly describes the clinical prevalence
and burden of the ESKAPE pathogens. By reviewing and analyzing the mechanisms of
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antimicrobial resistance, this literature review provides directions for researchers to develop new
antimicrobial innovations to reduce ESKAPE infectivity and improve patient outcomes.
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